A New Peak in the Treatment of Dry AMD
BluePeak™ imaging: a new clinical endpoint.
Dry AMD is the next major frontier for the pharmaceutical industry with more than 16 new therapeutics under development, many in late stage Phase II and III clinical study. BluePeak blue laser autofluorescence is playing a key role in dry AMD studies by tracking areas of geographic atrophy and providing a long-sought clinical endpoint for measuring response to these new therapeutics.
<   1   2   3   4   >